Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07304154 · ClinicalTrials.gov registry record · Phase 1
A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases
A Phase 1 study, sponsored by Kite, A Gilead Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
NCT07304154 is a Phase 1 study that is actively recruiting participants, run by Kite, A Gilead Company. The registered enrollment target is 52 participants.
The verdict
NCT07304154, a Phase 1 study, is actively recruiting participants, sponsored by Kite, A Gilead Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
Study Summary
This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study are: * To evaluate the safety and tolerability of KITE-363 in participants with autoimmune neurologic diseases * To determine the recommended dose for Phase 1b. * To evaluate the preliminary efficacy of KITE-363 in participants with autoimmune neurologic diseases.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- BIOLOGICAL KITE-363
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2026-04-10 |
| Est. Completion | 2029-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07304154
The ClinicalTrials.gov registry entry for NCT07304154 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kite, A Gilead Company, which has 28 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Cyclophosphamide is the first listed.
NCT07304154 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07304154 about?
NCT07304154 is a clinical study titled "A Study Evaluating the Safety and Efficacy of KITE-363 in Relapsed/Refractory Autoimmune Neurologic Diseases". This study will have two Phases: Phase 1a and Phase 1b. The goals of this clinical study are to learn more about the study drug KITE-363, by evaluating its safety, tolerability and efficacy in participants with relapsed/refractory autoimmune neurologic diseases. The primary objectives of this study...
What is the current status of trial NCT07304154?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2026-04-10. Estimated completion is 2029-06.
What interventions are being tested in trial NCT07304154?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), KITE-363 (BIOLOGICAL).
Who is sponsoring clinical trial NCT07304154?
This trial is sponsored by Kite, A Gilead Company, which has 28 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.